Policy / Regulatory

NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three‑Agency Regulatory Adjustment

CompanyDeals

NeuShen Therapeutics Closes Oversubscribed Series B Exceeding USD 80 Million to Accelerate Global CNS Pipeline

Policy / Regulatory

NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non‑Oral Dosage Forms

CompanyDrug

Hengrui Pharmaceuticals’ Oral GLP‑1R Agonist HRS‑7535 NDA Accepted by NMPA for Type 2 Diabetes, Joining China’s Incretin Race

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties
CompanyDeals

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

CompanyDrug

Zhongsheng Files China Trial Application to Expand Onradivir into High‑Risk Influenza A Patients, Broadening Its First‑in‑Class PB2 Inhibitor Franchise

CompanyDeals

PegBio Signs R&D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long‑Acting Delivery for Metabolic Diseases

CompanyDrug

Cutia Therapeutics’ CU‑20101 BLA Accepted by NMPA for Moderate to Severe Glabellar Lines, Advancing a Safer Botulinum Toxin Type A

Biocytogen Signs Non‑Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D
CompanyDeals

Biocytogen Signs Non‑Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D

CompanyDrug

Haixi Pharma Completes Phase I of Oral HX9428 in nAMD with Visual Gains, Files IND for DME Phase IIa as FDA Fast Track Asset Expands

CompanyDrug

Hansoh’s HS‑20093 Risvutatug Rezetecan NDA Accepted by NMPA for Small Cell Lung Cancer After First Global Phase III OS Win for a B7‑H3 ADC

CompanyDrug

Ocumension Completes Enrollment in China Phase III Trial of OT‑211 for Dry Eye Disease, Aligned with Global COMET Pivotal Program